We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
(-1.9%)
Cap. Flow
-$5.51M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.46M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.13M |
| 3 |
MediciNova
MNOV
|
+$969K |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$866K |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$856K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$2.78M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.32M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$1.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$1.01M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$938K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Nektar Therapeutics
NKTR
$2.39B
| $632K | 0.56% |
863
-138
| -14% | -$159K |
|
|
SYRS
127
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $630K | 0.56% |
+6,172
| New | +$764K |
|
|
ACGN
128
DELISTED
Aceragen Inc
ACGN
| $626K | 0.55% |
3,493
+660
| +23% | +$154K |
|
129
Rigel Pharmaceuticals
RIGL
$680M
| $617K | 0.55% |
21,799
+511
| +2% | +$18.2K |
|
|
MLNT
130
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $615K | 0.54% |
19,373
+9,567
| +98% | +$344K |
|
131
Arcus Biosciences
RCUS
$3.57B
| $609K | 0.54% |
+49,734
| New | +$780K |
|
|
132
Fidelity MSCI Information Technology Index ETF
FTEC
$19.9B
| $608K | 0.54% |
11,009
-50,996
| -82% | -$2.78M |
|
133
Direxion Daily Technology Bull 3x ETF
TECL
$5.14B
| $586K | 0.52% |
+43,990
| New | +$572K |
|
134
Alaunos Therapeutics
TCRT
$4.74M
| $574K | 0.51% |
1,267
+84
| +7% | +$53.3K |
|
|
KERX
135
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $544K | 0.48% |
144,564
-54,525
| -27% | -$265K |
|
|
SIOX
136
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $486K | 0.43% |
26,863
+9,567
| +55% | +$141K |
|
137
Gyre Therapeutics
GYRE
$662M
| $362K | 0.32% |
+4,141
| New | +$726K |
|
138
Itaú Unibanco
ITUB
$91.3B
| $241K | 0.21% |
47,901
+25,348
| +112% | +$157K |
|
139
Alibaba
BABA
$269B
| $194K | 0.17% |
1,045
-108
| -9% | -$20.6K |
|
140
Petrobras Class A
PBR.A
$107B
| $161K | 0.14% |
18,269
+11,170
| +157% | +$127K |
|
141
HDFC Bank
HDB
$119B
| $149K | 0.13% |
5,668
-520
| -8% | -$13K |
|
142
Ambev
ABEV
$47.3B
| $147K | 0.13% |
31,782
+16,298
| +105% | +$95.7K |
|
143
America Movil
AMX
$78.1B
| $105K | 0.09% |
6,308
-1,533
| -20% | -$26.5K |
|
144
Sociedad Química y Minera de Chile
SQM
$19.6B
| $84K | 0.07% |
1,743
-358
| -17% | -$18.8K |
|
145
Fomento Económico Mexicano
FMX
$43.3B
| $78K | 0.07% |
883
-250
| -22% | -$22.1K |
|
146
Adobe
ADBE
$89.5B
| $66K | 0.06% |
271
| – | – |
|
147
Cisco
CSCO
$450B
| $63K | 0.06% |
1,456
| – | – |
|
148
JD.com
JD
$40.8B
| $61K | 0.05% |
1,566
-14
| -0.9% | -$540 |
|
149
Visa
V
$677B
| $57K | 0.05% |
428
| – | – |
|
150
Johnson & Johnson
JNJ
$635B
| $49K | 0.04% |
406
| – | – |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.
- Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
- Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
- Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
- Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
- Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
- Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.
Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.